Frontiers in Medicine (Apr 2022)
The Relationship Among Intestinal Bacteria, Vitamin K and Response of Vitamin K Antagonist: A Review of Evidence and Potential Mechanism
- Han Yan,
- Yi Chen,
- Yi Chen,
- Yi Chen,
- Hong Zhu,
- Hong Zhu,
- Wei-Hua Huang,
- Wei-Hua Huang,
- Wei-Hua Huang,
- Xin-He Cai,
- Xin-He Cai,
- Xin-He Cai,
- Dan Li,
- Dan Li,
- Dan Li,
- Ya-Juan Lv,
- Ya-Juan Lv,
- Ya-Juan Lv,
- Si-Zhao,
- Si-Zhao,
- Si-Zhao,
- Hong-Hao Zhou,
- Hong-Hao Zhou,
- Hong-Hao Zhou,
- Fan-Yan Luo,
- Fan-Yan Luo,
- Wei Zhang,
- Wei Zhang,
- Wei Zhang,
- Xi Li,
- Xi Li,
- Xi Li
Affiliations
- Han Yan
- Department of Pharmacy, The Second Xiangya Hospital, Central South University, Changsha, China
- Yi Chen
- Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, China
- Yi Chen
- Institute of Clinical Pharmacology, Central South University, Hunan Key Laboratory of Pharmacogenetics, Changsha, China
- Yi Chen
- National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China
- Hong Zhu
- National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China
- Hong Zhu
- Department of Cardiovascular Surgery, Xiangya Hospital, Central South University, Changsha, China
- Wei-Hua Huang
- Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, China
- Wei-Hua Huang
- Institute of Clinical Pharmacology, Central South University, Hunan Key Laboratory of Pharmacogenetics, Changsha, China
- Wei-Hua Huang
- National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China
- Xin-He Cai
- Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, China
- Xin-He Cai
- Institute of Clinical Pharmacology, Central South University, Hunan Key Laboratory of Pharmacogenetics, Changsha, China
- Xin-He Cai
- National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China
- Dan Li
- Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, China
- Dan Li
- Institute of Clinical Pharmacology, Central South University, Hunan Key Laboratory of Pharmacogenetics, Changsha, China
- Dan Li
- National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China
- Ya-Juan Lv
- Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, China
- Ya-Juan Lv
- Institute of Clinical Pharmacology, Central South University, Hunan Key Laboratory of Pharmacogenetics, Changsha, China
- Ya-Juan Lv
- National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China
- Si-Zhao
- Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, China
- Si-Zhao
- Institute of Clinical Pharmacology, Central South University, Hunan Key Laboratory of Pharmacogenetics, Changsha, China
- Si-Zhao
- National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China
- Hong-Hao Zhou
- Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, China
- Hong-Hao Zhou
- Institute of Clinical Pharmacology, Central South University, Hunan Key Laboratory of Pharmacogenetics, Changsha, China
- Hong-Hao Zhou
- National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China
- Fan-Yan Luo
- National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China
- Fan-Yan Luo
- Department of Cardiovascular Surgery, Xiangya Hospital, Central South University, Changsha, China
- Wei Zhang
- Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, China
- Wei Zhang
- Institute of Clinical Pharmacology, Central South University, Hunan Key Laboratory of Pharmacogenetics, Changsha, China
- Wei Zhang
- National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China
- Xi Li
- Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, China
- Xi Li
- Institute of Clinical Pharmacology, Central South University, Hunan Key Laboratory of Pharmacogenetics, Changsha, China
- Xi Li
- National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China
- DOI
- https://doi.org/10.3389/fmed.2022.829304
- Journal volume & issue
-
Vol. 9
Abstract
The vitamin K antagonist is a commonly prescribed effective oral anticoagulant with a narrow therapeutic range, and the dose requirements for different patients varied greatly. In recent years, studies on human intestinal microbiome have provided many valuable insights into disease development and drug reactions. A lot of studies indicated the potential relationship between microbiome and the vitamin K antagonist. Vitamin K is absorbed by the gut, and the intestinal bacteria are a major source of vitamin K in human body. A combined use of the vitamin K antagonist and antibiotics may result in an increase in INR, thus elevating the risk of bleeding, while vitamin K supplementation can improve stability of anticoagulation for oral vitamin K antagonist treatment. Recently, how intestinal bacteria affect the response of the vitamin K antagonist remains unclear. In this review, we reviewed the research, focusing on the physiology of vitamin K in the anticoagulation treatment, and investigated the potential pathways of intestinal bacteria affecting the reaction of the vitamin K antagonist.
Keywords
